Background. Acellular pertussis (aP) and whole-cell (wP) pertussis vaccines are presumed to have similar short-term (<3 years after completion of the primary series) efficacy. However, vaccine effect varies between individual pertussis vaccine formulations, and many originally studied formulations are now unavailable. An updated analysis of the short-term protective effect of pertussis vaccines limited to formulations currently on the market in developed countries is needed.
Despite high rates of vaccine coverage, pertussis incidence has recently increased dramatically in many countries that previously had achieved good control of pertussis [1, 2] . Some of the largest increases in incidence have been among age groups that have completed a childhood pertussis vaccine series [3] . This shift in the burden of disease has been attributed, in part, to the fact that immunity to pertussis is not lifelong, whether after natural infection or vaccination [4] . Multiple observational studies have indicated that the immunity conferred by childhood acellular pertussis (aP) vaccines rapidly wanes in the first few years after completion of the childhood series [5] [6] [7] [8] [9] . In contrast, receipt of even a single dose of whole-cell pertussis (wP) vaccine as part of the childhood series confers more durable protection against pertussis [10, 11] .
Acellular pertussis vaccines were initially licensed based on data suggesting that, as a group, they had similar short-term (<3 years after completion of a primary series) efficacy as wP formulations [12] , but were less reactogenic [13] . These data came from multiple large vaccine efficacy and effectiveness studies that evaluated multiple comparator aP and wP formulations, whose individual performance varied substantially between studies, and many of which are no longer commercially available [14] [15] [16] [17] [18] [19] [20] [21] . Consequently, modern assumptions regarding both the absolute and relative protective effects of these vaccines may not be valid [22] . Evidence-based estimates are needed to provide context for modeling studies of populationlevel disease risk due to waning immunity [23] and for policy decisions regarding pertussis vaccine implementation. They can also serve as a performance benchmark for clinical trials and for novel pertussis vaccines currently in development.
In this systematic review and meta-analysis, we address this critical knowledge gap by assessing the protective effect of only those pertussis vaccines currently on the market. Our review applied standards developed by the Child Health Epidemiology Reference Group (CHERG) allowing for the systematic classification of evidence indicating the effect of various interventions on child morbidity and mortality. We generated estimates of the protective effect of both aP and wP vaccine against child morbidity, particularly as modeled by the Lives Saved Tool (LiST), a resource developed to allow countries to model the impact of maternal, neonatal, and child health interventions prior to implementation [24] .
METHODS

Literature Search
We conducted our systematic review and meta-analysis according to the standards for intervention reviews developed by CHERG [25] . We searched PubMed, the Cochrane Library, Web of Science, EMBASE, and the World Health Organization (WHO) Regional Databases, with no date restrictions, for English-language studies using the following search terms: pertussis, whooping cough, DTwP, DTaP, vaccine, efficacy, morbidity, and mortality. Following de-duplication, one reviewer (T. R. F.) screened all titles and abstracts to assess eligibility for inclusion. Any uncertainty during the screening process was resolved by discussion between the reviewer and principal investigator (S. B. O.).
Study Selection
Publications were included if they produced either (1) a pertussis vaccine efficacy or effectiveness estimate against a relevant outcome (all-cause mortality, pertussis-specific mortality, pertussis-specific hospitalization, or incidence or risk of typical or severe pertussis disease); or (2) an estimate of risk or odds of acquisition of pertussis with respect to time since completion of vaccination series. After our initial search, a meta-analysis on the duration of protection after childhood aP immunization was published [23] . For this analysis, we focused on the studies identified during our search that reported estimates of short-term efficacy or effectiveness to generate point estimates of aP and wP vaccine effect. We did not exclude publications based on type of study, which included randomized controlled trials (RCTs) and observational designs, including case-control, cohort, household contact, and screening studies (vaccine effectiveness computed on the basis of population coverage data and the proportion of cases vaccinated [26] ). Studies that did not evaluate absolute efficacy (ie, compared to a placebo or an unvaccinated comparison population) were included if they contained data on the protective effect of wP or aP vaccine against severe pertussis or hospitalizations due to pertussis. Studies conducting an intent-to-treat analysis were included if data against a relevant outcome were available and if >1 dose of pertussis vaccine was administered; these studies underwent additional examination to ensure consistency of assumptions and strength of evidence.
The included studies evaluated pertussis incidence, odds or risk of pertussis infection, and vaccine efficacy and effectiveness estimates for children <6 years of age within 3 years after completion (>3 doses, with or without booster doses) of a primary pertussis vaccine series. No minimum duration of follow-up was required for study inclusion. Study outcomes were required to be based on the current WHO definition of (1) "typical" pertussis (>14 days of cough with at least one of the following: paroxysmal cough, inspiratory whoop, or posttussive vomiting, in addition to laboratory confirmation [27] ); or (2) "severe" pertussis (>21 days of paroxysmal cough with laboratory confirmation of Bordetella pertussis infection, or epidemiological linkage [28] ). Studies using less stringent clinical criteria were also included if their laboratory criteria provided a high level of confidence for pertussis infection (eg, positive culture or polymerase chain reaction assay for B. pertussis).
Only studies that evaluated aP or wP formulations that were available at the time of our search (November 2013) were included (Tables 1 and 2 ). Market availability of pertussis vaccines was assessed by cross-referencing the formulations used in studies against 3 sources of market information (when available): standard reference texts [29, 30] , manufacturer product information pages, and/or inserts available online. Any uncertainty regarding the availability of a particular vaccine formulation was resolved through direct contact with the manufacturer.
Data Extraction
Key variables were abstracted to grade each study according to the CHERG adaptation of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) technique [25] . Effect measures from both efficacy and effectiveness trials were abstracted, with vaccine effectiveness calculated as 1 minus the odds ratio or 1 minus the relative risk following the methodology used by the respective study. We defined vaccine efficacy as an estimate of protective effect generated from an RCT, All research studies meeting the inclusion criteria and the relevant variables were abstracted into an Excel spreadsheet by one reviewer (T. R. F.).
Quality Assessment
We employed the CHERG-adapted GRADE process in ranking the quality of study evidence by 4 criteria: study design, study quality, relevance to the objectives of the review, and consistency across studies [25] .
Statistical Analysis
Studies yielding sufficient quality of evidence and sharing characteristics with other studies that would make them appropriate for a pooled analysis underwent fixed-and random-effects metaanalyses. Meta-analyses were stratified on type of vaccine (aP or wP) and type of study (efficacy or effectiveness). Per-protocol and intent-to-treat data were pooled within these strata. Heterogeneity between studies was evaluated using the I 2 statistic. Studies demonstrating low heterogeneity (I 2 < 50%) were pooled, and we took a conservative approach and presented overall effect estimates from the random-effects model rather than the fixedeffects model [31] to account for known and potential heterogeneity in pertussis vaccine performance. We then applied the CHERG rules for generating estimated intervention effects for use in LiST as appropriate. We did not perform comparative analyses of protective effect among the different aP vaccines. We conducted 2 sensitivity analyses, first removing the lowest GRADE-ranked study from the meta-analysis and assessing changes in effect size and significance, then removing any study contributing >50% of the total weight to determine impact on pooled effect size.
Meta-analyses were performed, and forest plots generated, using Microsoft Excel 2013 and Review Manager 5.2 software.
RESULTS
Literature Search Results
The initial literature search yielded 3985 titles. Of these, 175 abstracts were reviewed for eligibility; from these, 28 full articles were assessed for eligibility (Figure 1 ). Ten articles were considered ineligible for various reasons, principally because the vaccines studied were no longer on the market. There were 6 articles with data on longer-term protective effect; however, for this analysis we focused on the 12 articles that evaluated the short-term (<3 years after the primary series) effect of pertussis vaccines (Table 3) . Following convention for CHERG intervention reviews, details of each of these studies and key variables were abstracted into a spreadsheet (Supplementary  Table) .
Ten studies evaluated vaccine efficacy or effectiveness of aP formulations currently on the market. Among these were 2 aP efficacy studies-these were RCTs conducted in Italy [14] and Sweden [15] that used similar vaccine dose schedules, methods, and duration of follow-up, and laboratory assays for pertussis infection, and reported vaccine efficacy against an identical outcome (ie, WHO-defined pertussis). There were no vaccine efficacy studies of on-market wP formulations (the Connaught wP formulation evaluated in the Italian [14] and Swedish [15] efficacy trials is no longer on the market). There were 8 aP effectiveness [6, 18, 20, 21, [32] [33] [34] [35] and 7 wP effectiveness [18, 20, 21, 33, [35] [36] [37] studies; these studies varied in design (case-control, prospective cohort, or screening), number and schedule of vaccine doses evaluated (ie, before or after booster doses), duration of follow-up, and methods for case ascertainment (eg, hospital-based surveillance, cases reported to public health authorities). All studies evaluated outcomes corresponding to the WHO clinical case definitions for pertussis; however, there were slight differences in the specific definitions used in each study-for example, one study assessed effectiveness against laboratory-confirmed "severe pertussis" according to a protocol-defined severity scale [35] .
Applying the CHERG-adapted GRADE procedure to each study (Table 4) and averaging the adjusted scores over each outcome resulted in the assignment of an overall outcome-specific quality of evidence grade of "high" to aP efficacy trials, "moderate-low" to aP effectiveness trials, and "moderate-low" to wP effectiveness trials (Table 5 and Supplementary Table) . Abbreviations: aP, acellular pertussis vaccine; CI, confidence interval; RCT, randomized controlled trial; wP, whole-cell pertussis vaccine. a Limitations listed are in addition to those inherent in study design.
b Applies only to studies included in meta-analysis. 
Effects of Interventions
Acellular Vaccine Efficacy
Meta-analysis of the 2 aP vaccine efficacy studies [14, 15] generated a random-effects pooled vaccine efficacy of 84% (95% confidence interval [CI], 81%-87%; P < .00001; Figure 2 ). Heterogeneity was not significant at I 2 = 0%. This pooled analysis combined efficacy estimates for a complete 3-dose series of the GlaxoSmithKline 3-component (Infanrix) and Connaught 5-component (Daptacel) formulations.
Acellular Vaccine Effectiveness
Five [6, 18, 20, 21, 32] of the 8 aP vaccine effectiveness studies were deemed appropriate for inclusion in further meta-analysis. Two of the 3 excluded studies [33, 34] computed aP vaccine effectiveness utilizing the screening method; these studies were considered low quality because of the potential for substantial bias in the input estimates of vaccine coverage and pertussis incidence on which the effectiveness calculation is based [26] . The third excluded study estimated vaccine effectiveness against a studyspecific (not WHO-defined) outcome [35] , which differed from all of the other studies. Meta-analysis of the 5 included aP vaccine effectiveness studies generated significant heterogeneity with I 2 = 74% ( Figure 3) ; therefore, we did not compute a pooled estimate. The estimates of vaccine effectiveness reported in these studies ranged from 74% (95% CI, 51%-86%) to 97% (95% CI, 91%-99%).
Whole-Cell Vaccine Effectiveness
Three [18, 20, 21] of the 7 wP vaccine effectiveness were deemed appropriate for inclusion in further meta-analysis. Similar to the meta-analysis of aP effectiveness studies, we excluded 3 studies because they provided vaccine effectiveness utilizing the screening method [33, 36, 37] , and the fourth was excluded because it provided aP vaccine effectiveness against a study-specific (not WHO-defined) outcome [35] , different from the 3 included studies. Meta-analysis of the 3 included wP vaccine effectiveness studies generated a random-effects pooled vaccine effectiveness of 94% (95% CI, 88%-97%; P < .00001; Figure 4 ). Heterogeneity was not significant at I 2 = 0%. This pooled analysis combined effect estimates for a complete 3-dose series of wP formulations from Pasteur/Mérieux, Behringwerke, and SmithKline Beecham. On the strength of evidence of effect of aP and wP vaccines against WHO-defined pertussis, we applied Rule 5 of the CHERG rule set for generating estimated intervention effects for use in LiST to the pooled estimate of aP vaccine efficacy and wP vaccine effectiveness (Table 5 ) [25] . The estimated effects of aP vaccine and wP vaccine on WHO-defined pertussis in children aged <5 years recommended for LiST use were thus 84% (95% CI, 81%-87%) and 94% (95% CI, 88%-97%), respectively.
DISCUSSION
In this systematic review and meta-analysis, we found that a complete 3-dose initial series of currently available aP or wP vaccines provides short-term protection against WHO-defined pertussis disease in children <6 years of age. However, our meta-analysis yielded a lower pooled effect size for on-market aP vaccines than for wP vaccines. Our study differs from previous meta-analyses that have focused only on vaccine efficacy trials, safety studies, aP (but not wP) vaccines, or longer-term effectiveness, or have not restricted their evaluation to studies of vaccines that are currently available on the market, or generated point estimates [23, 38] .
These point estimates for on-market aP and wP vaccine effect corroborate observations regarding their relative real-world performance, and provide context for the resurgence in pertussis seen in some countries. Multiple hypotheses have been put forward to explain why aP vaccines have not prevented, or have contributed to, this rise in pertussis incidence [22] . The lower initial potency of aP vaccines compared with wP vaccines-as reflected by the lower pooled estimate of protective effect-is probably one reason why pertussis has reemerged among age groups that have just completed their pertussis vaccine series, even before their immunity has begun to wane. Indeed, the lower primary efficacy of aP vaccines compared with that of wP vaccines may partly explain why the protection conferred by aP vaccines wanes more rapidly [23] .
The results of this study have public health implications. From the standpoint of disease control, our point estimates for both aP and wP vaccine effect are below or just meet the projected crude herd immunity threshold for pertussis of 92%-94% [39] . Thus, although pertussis vaccines have had a dramatic impact on the overall disease burden in many countries, the currently available formulations will be insufficient to achieve complete elimination, even if vaccine coverage could be increased to 100%.
Our meta-analysis has some limitations. Pooled estimates for aP and wP vaccine effect may not be representative of all vaccine formulations, which may limit the generalizability of our effect estimates to vaccines that were not included in the metaanalysis. Heterogeneity in performance between individual aP and wP vaccines is well known. For example, the aP vaccine formulations used in the Italian [14] and Swedish [15] efficacy trials were superior to the comparator wP vaccine, a Connaughtdeveloped wP preparation that is no longer on the market. This variability in aP and wP vaccine performance is one reason that previous systematic reviews have avoided estimating overall effect sizes for aP and wP vaccines [38] . In contrast, we focused only on currently available vaccines, and excluded studies from the pooled analysis that combined data from multiple aP or wP formulations (some of which are no longer available) prior to reporting effect estimates, as well as observational studies of insufficient consistency in methodology (eg, screening studies) or reporting (eg, nonstandard case definitions) to warrant inclusion in our analysis, even if they offered effect estimates for a wider range of vaccines. As a result, we were able to generate pooled estimates that are both precise (nonoverlapping confidence intervals) and relevant.
We did not compute a pooled estimate for the 5 aP vaccine effectiveness studies included in the meta-analysis due to significant heterogeneity (I 2 = 74%). These studies exhibited variability in study design, dosage schedules, methods for case ascertainment, and reporting of overall effect (Table 3) , which may introduce substantial bias. Estimates from case-control (and case-contact) studies may have varying degrees of bias (eg, classification and/or ascertainment) due to differences in the approach to identifying vaccination status and pertussis cases. Three of these 5 studies evaluated 3 doses of vaccine, whereas the other 2 assessed >3 doses [32] or 5 doses [6] . Two studies combined data from multiple aP formulations and reported only a single estimate of vaccine effectiveness [6, 32] , precluding evaluation of any individual formulation; furthermore, one of these combined estimates included data from a formulation that is no longer available [32] . Finally, 3 studies [18, 20, 21] had a small number of cases, resulting in wide confidence intervals for the effect estimate. Another limitation is that most of the studies represented in the pooled estimate utilized a 2-, 4-, 6-month dosing schedule (only one study [21] used a 3-, 4-, 5-month schedule). Similarly, there were too few studies with outcome data after <3 doses to adequately evaluate an incomplete vaccine series. As such, our pooled estimates may not be generalizable to populations exposed to alternative dose schedules or to <3 vaccine doses. Only one of the studies included in the meta-analyses assessed aP vaccine effectiveness in a low-income country (Senegal) [20] , and this difference in setting may impact pertussis vaccine performance and thereby contribute to statistical heterogeneity. This could be attributable to regional differences in pertussis epidemiology or other factors known to impact the immunogenicity or effectiveness of childhood vaccines (eg, interference by maternal antibodies, nutritional status, household size). Notably, the Senegal study also found that aP vaccine was inferior to the comparator wP vaccine [20] , similar to our overall findings. More data are needed from a broader range of countries employing a variety of dose schedules to provide a more complete assessment of pertussis vaccination strategies.
In conclusion, in this systematic review and meta-analysis focusing on the short-term protective effect of currently available childhood pertussis vaccines, we determined an overall protective effect of 84% for aP vaccines and 94% for wP vaccines. These results provide context for the observed resurgence in pertussis and the apparent rapidly waning immunity to pertussis in the population, and present a standard against which newer immunization strategies or vaccine formulations should be evaluated. Improved vaccines may be needed to achieve pertussis control.
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